Indicator Explainer
Everolimus
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C48387. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Everolimus (C48387)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C48387. NCI definition, reproduced without modification under CC BY 4.0.
- PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation. — Int J Biol Macromol, 2026-10-06 (PMID 42838165; literature)
- Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients-Results From Two Randomized Controlled Trials. — Clin Transplant, 2026-10-01 (PMID 42853965; literature)
- Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial. — J Med Genet, 2026-10-22 (PMID 42562625; literature)
- Everolimus for Tinnitus: A Questionable Causal Chain [Letter]. — Drug Des Devel Ther, 2026-10-16 (PMID 42903802; literature)
- The long isoform of FABP6 facilitates WWP2-mediated PTEN ubiquitination to activate AKT/mTOR signalling and contributes to reduced everolimus sensitivity in clear cell renal cell carcinoma. — Clin Transl Med, 2026-10-01 (PMID 42926320; literature)
- The efficacy of standard-dose versus reduced-dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study. — J Neuroendocrinol, 2026-10-01 (PMID 42833281; literature)